Renalytix Plc (AIM:RENX)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 7.87M |
| Revenue (ttm) | 2.45M |
| Net Income (ttm) | -14.79M |
| Shares Out | 437.02M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,584 |
| Average Volume | 1,536,046 |
| Open | 1.600 |
| Previous Close | 1.800 |
| Day's Range | 1.600 - 2.000 |
| 52-Week Range | 1.600 - 15.500 |
| Beta | 1.97 |
| RSI | 13.46 |
| Earnings Date | Jun 24, 2026 |
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl... [Read more]
Financial Performance
In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.
Financial numbers in USD Financial StatementsNews
Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
New results and three presentations at ASN Kidney Week underscore kidneyintelX.dkd as a precision-medicine standard for CKD NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: R...
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15, ...
MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities. NEW YORK , July 21, 2025 /PRNewswire/ -- Renalytix Pl...
Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025
LONDON and NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management...